NO20005352L - ascorbate - Google Patents

ascorbate

Info

Publication number
NO20005352L
NO20005352L NO20005352A NO20005352A NO20005352L NO 20005352 L NO20005352 L NO 20005352L NO 20005352 A NO20005352 A NO 20005352A NO 20005352 A NO20005352 A NO 20005352A NO 20005352 L NO20005352 L NO 20005352L
Authority
NO
Norway
Prior art keywords
ascorbate
useful
treatment
cns disorders
certain cns
Prior art date
Application number
NO20005352A
Other languages
Norwegian (no)
Other versions
NO20005352D0 (en
Inventor
Michael Urquhart
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of NO20005352L publication Critical patent/NO20005352L/en
Publication of NO20005352D0 publication Critical patent/NO20005352D0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Paroksetinaskorbat er nyttig ved behandling av visse CNS-lidelser.Paroxetine ascorbate is useful in the treatment of certain CNS disorders.

NO20005352A 1998-04-25 2000-10-24 ascorbate NO20005352D0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9808896.6A GB9808896D0 (en) 1998-04-25 1998-04-25 Novel compound
PCT/GB1999/001244 WO1999055698A1 (en) 1998-04-25 1999-04-23 Paroxetine ascorbate

Publications (2)

Publication Number Publication Date
NO20005352L true NO20005352L (en) 2000-10-24
NO20005352D0 NO20005352D0 (en) 2000-10-24

Family

ID=10831008

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005352A NO20005352D0 (en) 1998-04-25 2000-10-24 ascorbate

Country Status (20)

Country Link
EP (1) EP1089995A1 (en)
JP (1) JP2002513019A (en)
KR (1) KR20010042977A (en)
CN (1) CN1297448A (en)
AP (1) AP2000001963A0 (en)
AU (1) AU3618499A (en)
BG (1) BG104940A (en)
BR (1) BR9909868A (en)
CA (1) CA2330055A1 (en)
EA (1) EA200001104A1 (en)
GB (1) GB9808896D0 (en)
HU (1) HUP0102116A3 (en)
ID (2) ID26654A (en)
IL (1) IL139081A0 (en)
NO (1) NO20005352D0 (en)
PL (1) PL343677A1 (en)
SK (1) SK15912000A3 (en)
TR (1) TR200003084T2 (en)
WO (1) WO1999055698A1 (en)
ZA (1) ZA200005912B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
IL159280A0 (en) * 2001-06-14 2004-06-01 Teva Pharma A process for preparing paroxetine hcl which limits formation of pink colored compounds
EP1469827B1 (en) * 2002-01-09 2017-12-27 Emisphere Technologies, Inc. Polymorphs of sodium 4- (4-chloro-2-hydroxybenzoyl)amino butanoate
CN118217851A (en) * 2018-10-30 2024-06-21 中国科学院化学研究所 Method for preparing amorphous substance of medicine or medicine intermediate with adjustable particle size

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
ES2058061T3 (en) * 1985-10-25 1994-11-01 Beecham Group Plc DERIVED FROM PIPERIDINE, ITS PREPARATION AND ITS USE AS A MEDICINAL PRODUCT.
US5276042A (en) * 1993-04-16 1994-01-04 Crenshaw Roger T Treatment of premature ejaculation
ES2117557B1 (en) * 1996-02-29 1999-07-01 Ferrer Int NEW PROCEDURE FOR OBTAINING (-) - TRANS -N-P-FLUOROBENZOILMETIL-4- (P-FLUOROFENIL) -3- ((3,4- (METHYLENDIOXI) PHENOXI) METHYL) -PIPERIDINE.

Also Published As

Publication number Publication date
CN1297448A (en) 2001-05-30
HUP0102116A2 (en) 2002-05-29
HUP0102116A3 (en) 2002-12-28
GB9808896D0 (en) 1998-06-24
IL139081A0 (en) 2001-11-25
WO1999055698A1 (en) 1999-11-04
AU3618499A (en) 1999-11-16
JP2002513019A (en) 2002-05-08
TR200003084T2 (en) 2001-02-21
CA2330055A1 (en) 1999-11-04
BR9909868A (en) 2000-12-19
ZA200005912B (en) 2001-12-19
AP2000001963A0 (en) 2000-12-31
ID26654A (en) 2001-01-25
SK15912000A3 (en) 2001-04-09
EP1089995A1 (en) 2001-04-11
ID26083A (en) 2000-11-23
KR20010042977A (en) 2001-05-25
EA200001104A1 (en) 2001-04-23
PL343677A1 (en) 2001-08-27
BG104940A (en) 2001-09-28
NO20005352D0 (en) 2000-10-24

Similar Documents

Publication Publication Date Title
NO993051L (en) Intranasal formulations for the treatment of sexual disorders
ID30062A (en) SUBSTITUTIONAL BENZOPIRAN ANALOGUE FOR TREATMENT OF RADANG
DE60022917D1 (en) Reboxetine for the treatment of migraine headache
DE60124684D1 (en) SULPHONAMIDO-SUBSTITUTED BROKEN BICYCLOALKYL DERIVATIVES
NO20005885D0 (en) Combination therapy for the treatment of refractory depression
NO20005884D0 (en) Combination therapy for the treatment of bipolar disorders
PT889886E (en) NEW FENANTRIDINES REPLACED IN POSITION 6
NO20005032L (en) Treatment of parasitic diseases by inhibition of cysteine proteases by the papain superfamily
NO20014617L (en) 1-Arensulfonyl-2-aryl pyrrolidine and piperidine derivatives for the treatment of CNS diseases
EE200000093A (en) Novel inhibitors of aggrecanase and matrix metalloproteinases for the treatment of arthritis
YU48698A (en) Carboxamide derivatives of pyrolidine, piperidine and hexahydroazepine for the treatment of thrombosis disorder
ID27214A (en) TRIAZOLOPIRIDINA FOR TREATMENT OF TROMBOSIS DISORDERS
NO20003211D0 (en) Triazine compounds for the treatment of CNS disorders
NO984432L (en) Procedure for the treatment of migraine pain
NO20005352L (en) ascorbate
BR0012921A (en) Calcally Compounds
DE60133385D1 (en) (+) - ALPHA- (2,3-DIMETHOXYPHENYL) -1- (2- (4-FLUORO-PHENYL) ETHYL) -4-PIPERIDINETHANOL OR PRODRUG THEREOF FOR THE TREATMENT OF DAMAGE SYMPTOMS OR COGNITIVE DISORDERS
NO990450D0 (en) Treatment of mental disorders
SG148840A1 (en) Indole derivatives useful for the treatment of cns disorders
NO20011892D0 (en) 3-tetrahydropyridin-4-yl indoles for the treatment of psychotic disorders
DK1133296T3 (en) New therapeutic use of nicergoline
NO20010390D0 (en) Treatment of anxiety disorders
NO20010569D0 (en) Protease inhibitors for use in the treatment of psoriasis
NO20005037L (en) Paroksetinmaleat
DE69917445D1 (en) CLEANING CARBOXALDEHYDE

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application